Reveal-Dx
Reveal-Dx develops RevealAI-Lung, an FDA-cleared AI-powered CADx software that analyzes chest CT scans to characterize lung nodules via its proprietary Malignancy Similarity Index, serving radiology departments and lung cancer screening programs at hospitals and health systems globally.
- Company typePrivate
- Founded2021
- HeadquartersSeattle, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Reveal-Dx does
Reveal-Dx is a Seattle-based private software company that develops RevealAI-Lung, an AI-powered computer-aided diagnosis (CADx) software for characterizing lung nodules detected on chest CT scans. The product generates a proprietary Malignancy Similarity Index (mSI) score from 3D lesion analysis using ensemble classification techniques and radiomic features, with results computed in seconds via single-click operation that integrates directly into radiologist PACS workflows. The software is the first AI-powered lung nodule CADx to achieve FDA 510(k) clearance (February 2026), MDR certification in the EU (November 2025), TGA clearance in Australia (September 2022), and Health Canada approval, and is the first Medical Imaging AI software to secure Medicare reimbursement in the US at $650 per scan under codes 0721T and 0722T.
The company operates a usage-based revenue model monetized through per-scan reimbursement and software licensing, distributed via a multi-channel strategy combining direct sales with regional exclusive partners: Sirona Medical (US), contextflow (EU), Riverain Technologies (Canada), Volpara Health (Australia/New Zealand), and Azra AI (oncology workflow integration). End customers are radiology departments, imaging centers, and lung cancer screening programs at hospitals and health systems. Clinical validation on over 1,500 patients demonstrated reduction in delayed cancer diagnoses from 45% to 25% at Royal United Hospitals Bath NHS Foundation Trust.
Reveal-Dx was formed in 2021 when Precision Medical Ventures acquired substantially all assets of Mindshare Medical and rebranded the entity, with Chris Wood appointed as CEO. The company has raised $4.25 million in a July 2024 funding round plus a $250,000 convertible note from Volpara Health, and holds U.S. Patent No. 10,255,997 covering the core mSI technology. The team is small (1-10 employees) and operates with a lean structure leveraging its distribution partner network for global commercialization across the US, EU, UK, Canada, Australia, and New Zealand.
Reveal-Dx firmographics
Firmographics- Name
- Reveal-Dx
- Legal name
- Reveal DX
- Website
- https://reveal-dx.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Reveal-Dx develops RevealAI-Lung, an FDA-cleared AI-powered CADx software that analyzes chest CT scans to characterize lung nodules via its proprietary Malignancy Similarity Index, serving radiology departments and lung cancer screening programs at hospitals and health systems globally.
- Ownership category
- akta.pro rank
Reveal-Dx industry classification
Industry- Product category
- AI-Powered Radiology Clinical Decision Support Software
- NAICS
- Medical and Diagnostic Laboratories (62151), Diagnostic Imaging Centers (621512)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Lung Cancer Screening & Pulmonary Nodule Clinic (HLAKANAI)
- akta.pro secondary industries
- Vendor Neutral Archive (VNA) & Enterprise Imaging Repositories (HLACALAC), Imaging & Diagnostic Interoperability (DICOM exchange, image sharing, VNA connectivity) (HLACABAM), Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)
Keywords
Where Reveal-Dx is headquartered
LocationHeadquarters
- HQ city
- Seattle
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Reveal-Dx business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- Per-scan/software licensing: Medicare reimbursement at $650 per scan under codes 0721T and 0722T. Software can be purchased directly from RevealDx or through distributors (Sirona in US). Revenue generated per usage/scan basis as healthcare facilities use the software for lung nodule assessment.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Usage-based | Pay-as-you-go | Per-scan usage model reimbursable under Medicare |
Go-to-market motion2 records
Distribution channels6 records
Marketing channels6 records
Reveal-Dx product offering
Product offeringCore offering
RevealDx develops RevealAI-Lung, an AI-powered Computer-Aided Diagnosis (CADx) software that analyzes chest CT scans to characterize lung nodules and generates a Malignancy Similarity Index (mSI) score to help radiologists assess malignancy risk and recommend appropriate follow-up. The product integrates directly into existing PACS systems, requires only a single click to operate, and returns results within seconds for use in lung cancer screening and incidental nodule management workflows. The software is FDA 510(k) cleared, CE Marked under MDR, TGA cleared, Health Canada approved, and reimbursable under Medicare codes 0721T and 0722T at $650 per scan.
Product overview
Reveal-Dx is a single-product company offering RevealAI-Lung, the world's first CADx (Computer-Aided Diagnosis) software for lung nodule characterization. The product uses radiomics and AI to analyze chest CT scans and generates a proprietary Malignancy Similarity Index (mSI) score. RevealAI-Lung is available through multiple integrated distribution channels including PACS vendors (Fuji, Riverain), workflow platforms (Sirona, contextflow), and strategic distributors (Volpara Health, Azra AI). The software is reimbursable under Medicare codes 0721T and 0722T at $650 per scan.
Differentiator
Problem solved
Functional benefit
Products and services
- RevealAI-Lung AI-powered Computer-Aided Diagnosis (CADx) software that analyzes chest CT scans to characterize incidentally or screen-detected lung nodules and generate a Malignancy Similarity Index (mSI) score, helping radiologists assess malignancy risk and select appropriate follow-up. Integrates directly into existing PACS systems with single-click operation and returns results within seconds. FDA 510(k) cleared, CE Marked under MDR, TGA cleared, Health Canada approved, and reimbursable under Medicare codes 0721T and 0722T at $650 per scan. Validated on more than 1,500 patients, reducing delayed cancer diagnoses from 45% to 25% and lowering unnecessary invasive procedures. Targeted at hospital systems, academic medical centers, and outpatient imaging networks.
Quantifiable outcome
- Reduced delayed cancer diagnoses from 45% to 25% in retrospective study at Royal United Hospitals Bath NHS Foundation Trust
- +3 more outcomes
Companies that use Reveal-Dx
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles1 record
Reveal-Dx technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration5 records
AI capability3 records
Feature4 records
Reveal-Dx partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core.
- Azra AIcoreIntegration of RevealAI-Lung's mSI score into Azra AI's enterprise oncology workflow platform for incidental findings and cancer care coordination. Builds on Azra AI's acquisition of Thynk health.
- Riverain TechnologiescoreProduct integration partnership. Riverain's ClearRead CT technology detects pulmonary nodules and provides volumetric data, then RevealDx's mSI characterizes malignancy risk. Riverain also distributes in Canada.
- Sirona MedicalcoreComprehensive distribution and collaboration partnership for US market. Sirona integrates RevealAI-Lung with their cloud-native radiology workflow software and automated lung nodule measurement tools.
- contextflowcoreExclusive distribution partnership for RevealDx products in the European Union and selected territories. contextflow integrates RevealAI-Lung into their SEARCH Lung CT platform, strengthening lung cancer screening capabilities with nodule characterization.
- Volpara HealthcoreStrategic partnership for Australia and New Zealand distribution. Volpara received exclusive rights to sell RevealAI-Lung in Australia/New Zealand and non-exclusive rights for US market. Volpara invested US$250,000 via convertible note.
Scale indicators5 records
Recent moves9 records
Expansion highlights6 records
Reveal-Dx competitors and assessment
Company assessmentDirect peers
- Optellum: Optellum develops AI for lung cancer prediction and lung nodule management on chest CT, including FDA-cleared Lung Cancer Prediction (Virtual Nodule Clinic). It is the closest direct competitor to RevealAI-Lung, serving the same radiology and lung cancer screening use cases.
- contextflow: contextflow offers the SEARCH Lung CT clinical decision support platform for nodule characterization on chest CT. It is also Reveal-Dx's exclusive EU distributor, making it both a direct competitor and a channel partner with overlapping lung nodule AI capabilities.
- Riverain Technologies: Riverain's ClearRead CT detects and characterizes pulmonary nodules and competes head-to-head with RevealAI-Lung on chest CT. It is also Reveal-Dx's integration partner and Canadian distributor, combining competitive overlap with channel partnership.
Broad incumbents
- Volpara Health: Volpara Health is a broader breast and lung cancer screening software platform that distributes RevealAI-Lung in Australia and New Zealand. It offers adjacent lung screening capabilities and is a peer in the lung cancer screening workflow category.
- Aidoc: Aidoc is a leading AI radiology platform offering a suite of FDA-cleared triage and workflow algorithms across multiple anatomies including chest CT. It competes for the same enterprise radiology AI budget and PACS integration footprint as Reveal-Dx.
- iCAD: iCAD offers AI-powered cancer detection and workflow solutions including ProFound AI for breast and ProFound AI Risk, with adjacent imaging AI capabilities. It is a broader incumbent in imaging AI with some overlap in cancer characterization workflows.
Emerging players
- Annalise.ai: Annalise.ai provides comprehensive AI decision support for chest X-ray and CT, including lung pathology detection. It is an emerging competitor in chest imaging AI with overlapping clinical use cases for radiologists and lung screening programs.
- Qure.ai: Qure.ai develops deep learning models for chest X-ray and CT interpretation including lung nodule and tuberculosis detection. It is an emerging global player with overlapping chest imaging AI applications and similar international regulatory expansion.
Others
- Sirona Medical: Sirona Medical is a cloud-native radiology workflow platform and Reveal-Dx's exclusive US distributor for RevealAI-Lung. While it can embed competing AI tools, its primary role is as a distribution and integration partner rather than a direct nodule AI competitor.
- Azra AI: Azra AI is an enterprise platform for incidental findings and oncology workflow automation that integrates RevealAI-Lung's mSI score. It is an adjacent ecosystem partner addressing oncology care coordination that complements Reveal-Dx's diagnostic capability.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights6 records
Customer concentration
Reveal-Dx compliance and trust
Trust signalCompliance4 records
Reveal-Dx financial estimates
Financial estimateRevenue estimate
Valuation estimate
Reveal-Dx leadership team
Management profileNumber of profiles
Profiles7 records
Reveal-Dx funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Reveal-Dx M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Reveal-Dx
What does Reveal-Dx do?
RevealDx develops RevealAI-Lung, an AI-powered Computer-Aided Diagnosis (CADx) software that analyzes chest CT scans to characterize lung nodules and generates a Malignancy Similarity Index (mSI) score to help radiologists assess malignancy risk and recommend appropriate follow-up. The product integrates directly into existing PACS systems, requires only a single click to operate, and returns results within seconds for use in lung cancer screening and incidental nodule management workflows. The software is FDA 510(k) cleared, CE Marked under MDR, TGA cleared, Health Canada approved, and reimbursable under Medicare codes 0721T and 0722T at $650 per scan.
Is Reveal-Dx a public or private company?
Reveal-Dx is a private company. It is classified as private equity controlled and is currently operating.
When was Reveal-Dx founded?
Reveal-Dx was founded in 2021. It employs 1 to 10 people.
Where is Reveal-Dx based?
Reveal-Dx is headquartered in Seattle, United States, in the North America region.
How does Reveal-Dx make money?
One revenue line is on record: per-scan/software licensing.
Who are Reveal-Dx's main competitors?
Direct peers on record are Optellum, contextflow and Riverain Technologies. Broad incumbents are Volpara Health, Aidoc and iCAD. Emerging players are Annalise.ai and Qure.ai. Others are Sirona Medical and Azra AI.
Does Reveal-Dx have an API?
No public API is recorded for Reveal-Dx.
What industry is Reveal-Dx in?
Reveal-Dx's product category is AI-Powered Radiology Clinical Decision Support Software. Its primary akta.pro industry code is HLAKANAI, Lung Cancer Screening & Pulmonary Nodule Clinic, with a secondary code of HLACALAC, Vendor Neutral Archive (VNA) & Enterprise Imaging Repositories. Its NAICS code is 62151 and its SIC code is 3841.